Ultra-stable MOF@MOF nanoplatform for photodynamic therapy sensitized by relieved hypoxia due to mitochondrial respiration inhibition
Source abstract
Abstract
Metal-organic frameworks (MOFs) with periodically arranged porphyrinic linkers avoiding the self-quenching issue of porphyrins in photodynamic therapy (PDT) have been widely applied. However, the porphyrinic MOFs still face challenges of poor stability under physiological conditions and limited photodynamic efficiency by the hypoxia condition of tumors. Herein, we fabricate the MOF@MOF structure with a protective MOF shell to improve the stability and relieve the hypoxia condition of tumors for sensitized PDT. Under protection of the MOF shell, the MOF@MOF structure can keep intact for 96 h under physiological conditions. Consequently, the tumoral accumulation efficiency is two folds of the MOF core. Furthermore, the MOF shell decomposes under acidic environment, and the loaded inhibitor of mitochondria pyruvate carrier (7-amino carboxycoumarins-2, 7ACC2) will be released. 7ACC2 inhibits the mitochondrial pyruvate influx and simultaneously blocks glucose and lactate from fueling the mitochondrial respiration, thereupon relieving the hypoxia condition of tumors. Under a 5-min laser irradiation, the 7ACC2 carrying MOF@MOF nanoplatforms induced doubled cellular apoptosis and reduced 70% of the tumor growth compared with the cargo-free MOF@MOF. In summary, the design of this stable and hypoxia self-relievable MOF@MOF nanoplatform will enlighten the future development of MOF-based nanomedicines and PDT. STATEMENT OF SIGNIFICANCE: Though widely used for photodynamic therapy (PDT) in previous studies, porphyrinic metal-organic frameworks (MOFs) still face challenges in poor stability under physiological conditions and limited photodynamic efficiency due to the hypoxia condition of tumors. In order to solve these problems, (1) we develop the MOF@MOF strategy to improve the physiological stability; (2) an inhibitor of mitochondria pyruvate carrier, 7-amino carboxycoumarins-2 (7ACC2), is loaded to inhibit the mitochondrial pyruvate influx and simultaneously block glucose and lactate from fueling the mitochondrial respiration, thereupon relieving the hypoxia condition of tumors. In comparison with previous studies, our strategy simultaneously improves stability and overcomes the limited PDT efficiency in the hypoxia tumor tissue, which will enlighten the future development of MOF-based nanomedicines and PDT.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Luminescence and Fluorescent Materials
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (65)
Show source-provided references
1. Photodynamic therapy for cancer10.1038/nrc1071 ↗
2. Nanoscale metal-organic framework for highly effective photodynamic therapy of resistant head and neck cancer10.1021/ja508679h ↗
3. Photodynamic therapy in oncology - mechanisms and clinical use10.1093/jnci/85.6.443 ↗
4. Dimensional reduction of Lewis acidic metal-organic frameworks for multicomponent reactions10.1021/jacs.1c03561 ↗
5. Near-infrared-ii plasmonic trienzyme-integrated metal-organic frameworks with high-efficiency enzyme cascades for synergistic trimodal oncotherapy
6. Biomineralized metal-organic framework nanoparticles enable intracellular delivery and endo-lysosomal release of native active proteins10.1021/jacs.8b04457 ↗
7. Fluorescent imaging-guided chemotherapy-and-photodynamic dual therapy with nanoscale porphyrin metal organic framework
8. A biomimetic theranostic O2-meter for cancer targeted photodynamic therapy and phosphorescence imaging10.1016/j.biomaterials.2017.10.021 ↗
9. DNAzyme-loaded metal-organic frameworks (MOFs) for self-sufficient gene therapy10.1002/anie.201902714 ↗
10. Nanoscale metal-organic framework confines zinc-phthalocyanine photosensitizers for enhanced photodynamic therapy10.1021/jacs.1c07379 ↗
11. Nanoscale metal-organic frameworks stabilize bacteriochlorins for type I and type II photodynamic therapy10.1021/jacs.0c02129 ↗
12. One-pot rapid synthesis of Cu2+-doped GOD@MOF to amplify the antitumor efficacy of chemodynamic therapy10.1021/acsami.3c00562 ↗
13. Interfering with lactate-fueled respiration for enhanced photodynamic tumor therapy by a porphyrinic mof nanoplatform
14. Heterodimers made of upconversion nanoparticles and metal-organic frameworks10.1021/jacs.7b07302 ↗
15. A singlet oxygen reservoir based on poly-pyridone and porphyrin nanoscale metal–organic framework for cancer therapy
16. Upconverted metal-organic framework Janus architecture for near-infrared and ultrasound co-enhanced high performance tumor therapy10.1021/acsnano.1c04280 ↗
17. Homotypic targeted photosensitive nanointerferer for tumor cell cycle arrest to boost tumor photoimmunotherapy10.1021/acsnano.2c06871 ↗
18. In situ polymerization on nanoscale metal-organic frameworks for enhanced physiological stability and stimulus-responsive intracellular drug delivery10.1016/j.biomaterials.2019.119365 ↗
19. Multifunctional nanoparticles by coordinative self-assembly of his tagged units with metal organic frameworks10.1021/jacs.6b11934 ↗
20. Selective surface PEGylation of UiO-66 nanoparticles for enhanced stability, cell uptake, and pH-responsive drug delivery10.1016/j.chempr.2017.02.005 ↗
21. Formulation of metal-organic framework-based drug carriers by controlled coordination of methoxy peg phosphate: boosting colloidal stability and redispersibility10.1021/jacs.1c03943 ↗
22. DNA-functionalized metal-organic framework nanoparticles for intracellular delivery of proteins10.1021/jacs.8b12705 ↗
23. General and direct method for preparing oligonucleotide-functionalized metal-organic framework nanoparticles10.1021/jacs.7b05633 ↗
24. ZrMOF nanoparticles as quenchers to conjugate DNA aptamers for target-induced bioimaging and photodynamic therapy10.1039/C8SC02210K ↗
25. Zr-based mofs shielded with phospholipid bilayers: improved biostability and cell uptake for biological applications10.1021/acs.chemmater.7b01329 ↗
26. Atypical hybrid metal-organic frameworks (MOFs): a combinative process for MOF-on-MOF growth, etching, and structure transformation10.1002/anie.201912986 ↗
27. Construction of flexible-on-rigid hybrid-phase metal-organic frameworks for controllable multi-drug delivery10.1002/anie.202008858 ↗
28. Metal-organic-framework-based hydrogen-release platform for multieffective helicobacter pylori targeting therapy and intestinal flora protective capabilities
29. Encapsulation of plasmid DNA by nanoscale metal-organic frameworks for efficient gene transportation and expression
30. Zeolitic imidazolate frameworks (ZIF-8) for biomedical applications: a review10.2174/0929867328666210608143703 ↗
31. Pyrrole/macrocycle/MOF supramolecular co-assembly for flexible solid state supercapacitors10.1016/j.cclet.2021.03.002 ↗
32. A biomimetic coordination nanoplatform for controlled encapsulation and delivery of drug-gene combinations10.1002/anie.201903417 ↗
33. Black phosphorus nanosheet encapsulated by zeolitic imidazole framework-8 for tumor multimodal treatments10.1021/acsami.1c04001 ↗
34. Cancer cell membrane camouflaged cascade bioreactor for cancer targeted starvation and photodynamic therapy10.1021/acsnano.7b02533 ↗
35. Hypoxia-induced epithelial-mesenchymal transition in cancers: HIF-1α and beyond10.3389/fonc.2020.00486 ↗
36. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia10.1007/s00280-006-0291-9 ↗
37. A dual functional nanoreactor for synergistic starvation and photodynamic therapy10.1021/acsami.0c01039 ↗
38. Novel YOF-based theranostic agents with a cascade effect for NIR-II fluorescence imaging and synergistic starvation/photodynamic therapy of orthotopic gliomas10.1021/acsami.2c05354 ↗
39. Drug-induced self-assembly cascade nanoreactor for synergistic tumor therapy10.1021/acsami.2c09947 ↗
40. Folic acid-modified cyclodextrin multivalent supramolecular assembly for photodynamic therapy10.1021/acs.biomac.2c00276 ↗
41. Supramolecular dual polypeptides induced tubulin aggregation for cancer theranostics10.1021/acs.jmedchem.2c01398 ↗
42. Differential effects of glucose deprivation on the cellular sensitivity towards photodynamic treatment-based production of reactive oxygen species and apoptosis-induction10.1016/j.febslet.2004.11.073 ↗
43. Targeting Warburg effect to rescue the suffocated photodynamic therapy: a cancer-specific solution10.1016/j.biomaterials.2023.122017 ↗
44. Photodynamic therapy by glucose transporter 1-selective light inactivation10.1021/acsomega.2c05042 ↗
45. Interruption of lactate uptake by inhibiting mitochondrial pyruvate transport unravels direct antitumor and radiosensitizing effects10.1038/s41467-018-03525-0 ↗
46. Glucose feeds the TCA cycle via circulating lactate10.1038/nature24057 ↗
47. Lactate metabolism in human lung tumors10.1016/j.cell.2017.09.019 ↗
48. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice
49. Advanced cancer starvation therapy by simultaneous deprivation of lactate and glucose using a mof nanoplatform10.1002/advs.202101467 ↗
50. Cd147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors10.1073/pnas.1106123108 ↗
51. Ovarian cancer relies on glucose transporter 1 to fuel glycolysis and growth: anti-tumor activity of BAY-876
52. Identification and optimization of the first highly selective GLUT1 inhibitor BAY-87610.1002/cmdc.201600276 ↗
53. Erythrocyte membrane cloaked metal-organic framework nanoparticle as biomimetic nanoreactor for starvation-activated colon cancer therapy10.1021/acsnano.8b05200 ↗
54. Heterogeneity of si-oh-al groups in hnay zeolites10.1039/FT9969200499 ↗
55. Degradation kinetic study of ZIF-8 microcrystals with and without the presence of lactic acid10.1039/D1RA07089D ↗
56. Degradation of ZIF-8 in phosphate buffered saline media10.1039/C9CE00757A ↗
57. Robust and tumor-environment-activated DNA cross-linker driving nanoparticle accumulation for enhanced therapeutics10.31635/ccschem.020.202000134 ↗
58. Effect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGA-mPEG nanoparticles10.1016/S0378-5173(03)00224-2 ↗
59. Engineering lactate-modulating nanomedicines for cancer therapy10.1039/D2CS00479H ↗
60. Lactate in solid malignant tumors: potential basis of a metabolic classification in clinical oncology10.2174/0929867043364711 ↗
61. Effects of a 30-km race upon salivary lactate correlation with blood lactate10.1016/j.cbpb.2006.07.001 ↗
62. Condurango glycoside-rich components stimulate DNA damage-induced cell cycle arrest and ROS-mediated caspase-3 dependent apoptosis through inhibition of cell-proliferation in lung cancer, in vitro and in vivo10.1016/j.etap.2013.12.004 ↗
63. Pluronic/heparin nanoparticles for chemo-photodynamic combination cancer therapy through photoinduced caspase-3 activation10.1021/acsanm.8b00572 ↗
64. Inhibition of H1N1 influenza virus-induced apoptosis by selenium nanoparticles functionalized with arbidol through ROS-mediated signaling pathways10.1039/C9TB00531E ↗
65. Dual key co-activated nanoplatform for switchable MRI monitoring accurate ferroptosis-based synergistic therapy10.1016/j.chempr.2022.03.009 ↗